BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve around the world, generating new variants that are of concern on the basis of their potential for altered transmissibility, pathogenicity, and coverage by vaccines and therapeutic agents 1 – 5 . Here we show that se...
Uložené v:
| Vydané v: | Nature (London) Ročník 596; číslo 7871; s. 273 - 275 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
London
Nature Publishing Group UK
12.08.2021
Nature Publishing Group |
| Predmet: | |
| ISSN: | 0028-0836, 1476-4687, 1476-4687 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve around the world, generating new variants that are of concern on the basis of their potential for altered transmissibility, pathogenicity, and coverage by vaccines and therapeutic agents
1
–
5
. Here we show that serum samples taken from twenty human volunteers, two or four weeks after their second dose of the BNT162b2 vaccine, neutralize engineered SARS-CoV-2 with a USA-WA1/2020 genetic background (a virus strain isolated in January 2020) and spike glycoproteins from the recently identified B.1.617.1, B.1.617.2, B.1.618 (all of which were first identified in India) or B.1.525 (first identified in Nigeria) lineages. Geometric mean plaque reduction neutralization titres against the variant viruses—particularly the B.1.617.1 variant—seemed to be lower than the titre against the USA-WA1/2020 virus, but all sera tested neutralized the variant viruses at titres of at least 1:40. The susceptibility of the variant strains to neutralization elicited by the BNT162b2 vaccine supports mass immunization as a central strategy to end the coronavirus disease 2019 (COVID-19) pandemic globally.
Samples of serum from individuals immunized with the BNT162b2 vaccine show neutralization activity against engineered SARS-CoV-2s bearing the spike mutations from B.1.617 and other variants. |
|---|---|
| AbstractList | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve around the world, generating new variants that are of concern on the basis of their potential for altered transmissibility, pathogenicity, and coverage by vaccines and therapeutic agents.sup.1-5. Here we show that serum samples taken from twenty human volunteers, two or four weeks after their second dose of the BNT162b2 vaccine, neutralize engineered SARS-CoV-2 with a USA-WA1/2020 genetic background (a virus strain isolated in January 2020) and spike glycoproteins from the recently identified B.1.617.1, B.1.617.2, B.1.618 (all of which were first identified in India) or B.1.525 (first identified in Nigeria) lineages. Geometric mean plaque reduction neutralization titres against the variant viruses--particularly the B.1.617.1 variant--seemed to be lower than the titre against the USA-WA1/2020 virus, but all sera tested neutralized the variant viruses at titres of at least 1:40. The susceptibility of the variant strains to neutralization elicited by the BNT162b2 vaccine supports mass immunization as a central strategy to end the coronavirus disease 2019 (COVID-19) pandemic globally. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve around the world, generating new variants that are of concern on the basis of their potential for altered transmissibility, pathogenicity, and coverage by vaccines and therapeutic agents . Here we show that serum samples taken from twenty human volunteers, two or four weeks after their second dose of the BNT162b2 vaccine, neutralize engineered SARS-CoV-2 with a USA-WA1/2020 genetic background (a virus strain isolated in January 2020) and spike glycoproteins from the recently identified B.1.617.1, B.1.617.2, B.1.618 (all of which were first identified in India) or B.1.525 (first identified in Nigeria) lineages. Geometric mean plaque reduction neutralization titres against the variant viruses-particularly the B.1.617.1 variant-seemed to be lower than the titre against the USA-WA1/2020 virus, but all sera tested neutralized the variant viruses at titres of at least 1:40. The susceptibility of the variant strains to neutralization elicited by the BNT162b2 vaccine supports mass immunization as a central strategy to end the coronavirus disease 2019 (COVID-19) pandemic globally. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve around the world, generating new variants that are of concern on the basis of their potential for altered transmissibility, pathogenicity, and coverage by vaccines and therapeutic agents.sup.1-5. Here we show that serum samples taken from twenty human volunteers, two or four weeks after their second dose of the BNT162b2 vaccine, neutralize engineered SARS-CoV-2 with a USA-WA1/2020 genetic background (a virus strain isolated in January 2020) and spike glycoproteins from the recently identified B.1.617.1, B.1.617.2, B.1.618 (all of which were first identified in India) or B.1.525 (first identified in Nigeria) lineages. Geometric mean plaque reduction neutralization titres against the variant viruses--particularly the B.1.617.1 variant--seemed to be lower than the titre against the USA-WA1/2020 virus, but all sera tested neutralized the variant viruses at titres of at least 1:40. The susceptibility of the variant strains to neutralization elicited by the BNT162b2 vaccine supports mass immunization as a central strategy to end the coronavirus disease 2019 (COVID-19) pandemic globally. Samples of serum from individuals immunized with the BNT162b2 vaccine show neutralization activity against engineered SARS-CoV-2s bearing the spike mutations from B.1.617 and other variants. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve around the world, generating new variants that are of concern on the basis of their potential for altered transmissibility, pathogenicity, and coverage by vaccines and therapeutic agents 1 – 5 . Here we show that serum samples taken from twenty human volunteers, two or four weeks after their second dose of the BNT162b2 vaccine, neutralize engineered SARS-CoV-2 with a USA-WA1/2020 genetic background (a virus strain isolated in January 2020) and spike glycoproteins from the recently identified B.1.617.1, B.1.617.2, B.1.618 (all of which were first identified in India) or B.1.525 (first identified in Nigeria) lineages. Geometric mean plaque reduction neutralization titres against the variant viruses—particularly the B.1.617.1 variant—seemed to be lower than the titre against the USA-WA1/2020 virus, but all sera tested neutralized the variant viruses at titres of at least 1:40. The susceptibility of the variant strains to neutralization elicited by the BNT162b2 vaccine supports mass immunization as a central strategy to end the coronavirus disease 2019 (COVID-19) pandemic globally. Samples of serum from individuals immunized with the BNT162b2 vaccine show neutralization activity against engineered SARS-CoV-2s bearing the spike mutations from B.1.617 and other variants. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve around the world, generating new variants that are of concern on the basis of their potential for altered transmissibility, pathogenicity, and coverage by vaccines and therapeutic agents1-5. Here we show that serum samples taken from twenty human volunteers, two or four weeks after their second dose of the BNT162b2 vaccine, neutralize engineered SARS-CoV-2 with a USA-WA1/2020 genetic background (a virus strain isolated in January 2020) and spike glycoproteins from the recently identified B.1.617.1, B.1.617.2, B.1.618 (all of which were first identified in India) or B.1.525 (first identified in Nigeria) lineages. Geometric mean plaque reduction neutralization titres against the variant viruses-particularly the B.1.617.1 variant-seemed to be lower than the titre against the USA-WA1/2020 virus, but all sera tested neutralized the variant viruses at titres of at least 1:40. The susceptibility of the variant strains to neutralization elicited by the BNT162b2 vaccine supports mass immunization as a central strategy to end the coronavirus disease 2019 (COVID-19) pandemic globally.Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve around the world, generating new variants that are of concern on the basis of their potential for altered transmissibility, pathogenicity, and coverage by vaccines and therapeutic agents1-5. Here we show that serum samples taken from twenty human volunteers, two or four weeks after their second dose of the BNT162b2 vaccine, neutralize engineered SARS-CoV-2 with a USA-WA1/2020 genetic background (a virus strain isolated in January 2020) and spike glycoproteins from the recently identified B.1.617.1, B.1.617.2, B.1.618 (all of which were first identified in India) or B.1.525 (first identified in Nigeria) lineages. Geometric mean plaque reduction neutralization titres against the variant viruses-particularly the B.1.617.1 variant-seemed to be lower than the titre against the USA-WA1/2020 virus, but all sera tested neutralized the variant viruses at titres of at least 1:40. The susceptibility of the variant strains to neutralization elicited by the BNT162b2 vaccine supports mass immunization as a central strategy to end the coronavirus disease 2019 (COVID-19) pandemic globally. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve around the world, generating new variants that are of concern on the basis of their potential for altered transmissibility, pathogenicity, and coverage by vaccines and therapeutic agents1-5. Here we show that serum samples taken from twenty human volunteers, two or four weeks after their second dose of the BNT162b2 vaccine, neutralize engineered SARS-CoV-2 with a USA-WA1/2020 genetic background (a virus strain isolated in January 2020) and spike glycoproteins from the recently identified B.1.617.1, B.1.617.2, B.1.618 (all of which were first identified in India) or B.1.525 (first identified in Nigeria) lineages. Geometric mean plaque reduction neutralization titres against the variant viruses-particularly the B.1.617.1 variant-seemed to be lower than the titre against the USA-WA1/2020 virus, but all sera tested neutralized the variant viruses at titres of at least 1:40. The susceptibility of the variant strains to neutralization elicited by the BNT162b2 vaccine supports mass immunization as a central strategy to end the coronavirus disease 2019 (COV1D-19) pandemic globally. |
| Audience | Academic |
| Author | Xia, Hongjie Dormitzer, Philip R. Liu, Jianying Zou, Jing Weaver, Scott C. Liu, Yang Cai, Hui Xie, Xuping Jansen, Kathrin U. Sahin, Ugur Muik, Alexander Shi, Pei-Yong Cutler, Mark Cooper, David Swanson, Kena A. |
| Author_xml | – sequence: 1 givenname: Jianying surname: Liu fullname: Liu, Jianying organization: Department of Microbiology and Immunology, University of Texas Medical Branch, Institute for Human Infections and Immunity, University of Texas Medical Branch – sequence: 2 givenname: Yang surname: Liu fullname: Liu, Yang organization: Department of Biochemistry and Molecular Biology, University of Texas Medical Branch – sequence: 3 givenname: Hongjie orcidid: 0000-0002-2520-7038 surname: Xia fullname: Xia, Hongjie organization: Department of Biochemistry and Molecular Biology, University of Texas Medical Branch – sequence: 4 givenname: Jing surname: Zou fullname: Zou, Jing organization: Department of Biochemistry and Molecular Biology, University of Texas Medical Branch – sequence: 5 givenname: Scott C. orcidid: 0000-0001-8016-8556 surname: Weaver fullname: Weaver, Scott C. organization: Department of Microbiology and Immunology, University of Texas Medical Branch, Institute for Human Infections and Immunity, University of Texas Medical Branch, Institute for Translational Sciences, University of Texas Medical Branch, Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Sealy Institute for Vaccine Sciences, University of Texas Medical Branch – sequence: 6 givenname: Kena A. orcidid: 0000-0002-3389-8414 surname: Swanson fullname: Swanson, Kena A. organization: Pfizer Vaccine Research and Development – sequence: 7 givenname: Hui surname: Cai fullname: Cai, Hui organization: Pfizer Vaccine Research and Development – sequence: 8 givenname: Mark surname: Cutler fullname: Cutler, Mark organization: Pfizer Vaccine Research and Development – sequence: 9 givenname: David surname: Cooper fullname: Cooper, David organization: Pfizer Vaccine Research and Development – sequence: 10 givenname: Alexander orcidid: 0000-0003-4561-2273 surname: Muik fullname: Muik, Alexander organization: BioNTech – sequence: 11 givenname: Kathrin U. surname: Jansen fullname: Jansen, Kathrin U. organization: Pfizer Vaccine Research and Development – sequence: 12 givenname: Ugur surname: Sahin fullname: Sahin, Ugur email: ugur.sahin@biontech.de organization: BioNTech – sequence: 13 givenname: Xuping orcidid: 0000-0003-0918-016X surname: Xie fullname: Xie, Xuping email: xuxie@utmb.edu organization: Department of Biochemistry and Molecular Biology, University of Texas Medical Branch – sequence: 14 givenname: Philip R. orcidid: 0000-0003-0671-6360 surname: Dormitzer fullname: Dormitzer, Philip R. email: philip.dormitzer@pfizer.com organization: Pfizer Vaccine Research and Development – sequence: 15 givenname: Pei-Yong orcidid: 0000-0001-5553-1616 surname: Shi fullname: Shi, Pei-Yong email: peshi@utmb.edu organization: Institute for Human Infections and Immunity, University of Texas Medical Branch, Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Institute for Translational Sciences, University of Texas Medical Branch, Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Sealy Institute for Vaccine Sciences, University of Texas Medical Branch |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34111888$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kstuEzEYhS1URNPCC7BAI9iAkIMv48ss06hApKpITYCl5fF4gquJndoziPTpcZtWJVWovLBkfef4v5wjcOCDtwC8xmiMEZWfUomZ5BARDBHlFYWbZ2CES8FhyaU4ACOEiIRIUn4IjlK6RAgxLMoX4JCWGGMp5QjMTs4XmJOaQNs543rbFN4OfdSdu9a9C74IbXEyxmOORaF9U4T-l43FfHIxh9PwA5Lit45O-z69BM9b3SX76u4-Bt8_ny6mX-HZty-z6eQMmlxUD7VhVjApaG0kZiWtqlrUmhlNKqYrzVvONCdlyxvSSCEs5UwwbUVbtxUW0tBj8H7ru47harCpVyuXjO067W0YkiKszG1KSllG3z1CL8MQfa4uUzyPABGGHqil7qxyvg25fXNjqiZc4Px_hXCm4B5qab3Ns8p7aV1-3uHf7uHN2l2pf6HxHiifxq6c2ev6YUeQmd7-6Zd6SEnN5he77Mf_s5PFz-n5Lv3mblZDvbKNWke30nGj7qOSAbkFTAwpRduqHJfbiOSaXacwUjepVNtUqpxKdZtKtclS8kh67_6kiG5FKcN-aePD8p5Q_QUC7OtV |
| CitedBy_id | crossref_primary_10_1016_j_apsb_2022_01_019 crossref_primary_10_20965_jdr_2022_p0007 crossref_primary_10_1016_j_resconrec_2024_107615 crossref_primary_10_1038_s41564_022_01135_7 crossref_primary_10_3389_fimmu_2021_804808 crossref_primary_10_1093_bib_bbab375 crossref_primary_10_1056_NEJMoa2110345 crossref_primary_10_3390_v14061211 crossref_primary_10_1038_s41392_021_00767_1 crossref_primary_10_1128_Spectrum_01882_21 crossref_primary_10_3390_molecules29235564 crossref_primary_10_1038_s41564_021_00972_2 crossref_primary_10_1007_s12275_021_1348_5 crossref_primary_10_1016_j_vaccine_2022_02_045 crossref_primary_10_1108_MEQ_01_2022_0018 crossref_primary_10_3389_fimmu_2022_836232 crossref_primary_10_1016_j_foodcont_2022_108845 crossref_primary_10_3389_fcimb_2021_771524 crossref_primary_10_3390_vaccines9101130 crossref_primary_10_1016_j_hsr_2022_100040 crossref_primary_10_3389_fcimb_2022_988604 crossref_primary_10_3390_pharmaceutics14010176 crossref_primary_10_1002_jcb_30432 crossref_primary_10_1016_j_jgg_2023_10_003 crossref_primary_10_3389_fimmu_2022_947320 crossref_primary_10_1038_s41591_022_02162_x crossref_primary_10_1016_j_chom_2022_02_015 crossref_primary_10_1016_j_ebiom_2021_103748 crossref_primary_10_3390_v14081603 crossref_primary_10_1038_s41586_021_03777_9 crossref_primary_10_3390_vaccines12050554 crossref_primary_10_1038_s41598_022_07849_2 crossref_primary_10_1126_sciimmunol_abp9962 crossref_primary_10_3390_life11111152 crossref_primary_10_1002_jmv_27676 crossref_primary_10_3389_fimmu_2022_935573 crossref_primary_10_1016_j_ajpath_2021_12_011 crossref_primary_10_3390_app12020665 crossref_primary_10_26508_lsa_202201415 crossref_primary_10_1007_s00705_021_05295_5 crossref_primary_10_1038_s41565_022_01174_5 crossref_primary_10_1186_s12889_022_13720_w crossref_primary_10_1002_jmv_28657 crossref_primary_10_3390_vaccines10091538 crossref_primary_10_3201_eid2711_211353 crossref_primary_10_3390_diseases10040112 crossref_primary_10_1016_j_vaccine_2023_04_070 crossref_primary_10_1097_GRF_0000000000000670 crossref_primary_10_3390_v14030597 crossref_primary_10_3390_biom12121742 crossref_primary_10_7774_cevr_2022_11_3_285 crossref_primary_10_1177_00333549221110300 crossref_primary_10_3389_fcimb_2021_781429 crossref_primary_10_3389_fmed_2022_849217 crossref_primary_10_1002_phar_2622 crossref_primary_10_1016_j_humgen_2024_201281 crossref_primary_10_1016_j_trsl_2022_06_004 crossref_primary_10_1128_JVI_01313_21 crossref_primary_10_3390_diagnostics13040643 crossref_primary_10_3390_vaccines10060874 crossref_primary_10_1038_s41586_021_04188_6 crossref_primary_10_1016_j_compbiolchem_2024_108139 crossref_primary_10_1080_14760584_2022_2044800 crossref_primary_10_1080_21645515_2022_2057161 crossref_primary_10_1371_journal_pone_0266701 crossref_primary_10_2217_fvl_2021_0277 crossref_primary_10_1038_s41421_022_00381_7 crossref_primary_10_1016_j_medj_2021_11_004 crossref_primary_10_1007_s15010_022_01759_1 crossref_primary_10_3390_vaccines11061127 crossref_primary_10_1080_22221751_2022_2161422 crossref_primary_10_1038_s42003_023_04955_3 crossref_primary_10_3390_vaccines10030411 crossref_primary_10_1016_j_heliyon_2023_e13952 crossref_primary_10_1139_cjpp_2021_0663 crossref_primary_10_3390_life13020304 crossref_primary_10_3390_v14091928 crossref_primary_10_4103_ijmr_ijmr_2544_21 crossref_primary_10_1038_s41541_022_00462_4 crossref_primary_10_3390_biomedicines9101303 crossref_primary_10_3390_life11090896 crossref_primary_10_1038_s41467_022_33284_y crossref_primary_10_1038_s41577_021_00592_1 crossref_primary_10_1038_s41392_022_00926_y crossref_primary_10_1128_jcm_00178_22 crossref_primary_10_1038_s41467_022_34439_7 crossref_primary_10_3389_fimmu_2022_1038712 crossref_primary_10_1016_j_coviro_2023_101349 crossref_primary_10_1016_j_jaip_2021_07_016 crossref_primary_10_1016_j_chom_2021_08_002 crossref_primary_10_3390_biom11101494 crossref_primary_10_1186_s12951_022_01687_0 crossref_primary_10_1016_j_clnesp_2024_01_021 crossref_primary_10_4014_jmb_2111_11026 crossref_primary_10_1080_22221751_2024_2412643 crossref_primary_10_1016_j_biopha_2021_112176 crossref_primary_10_1007_s11356_022_22333_0 crossref_primary_10_1016_j_meegid_2021_105088 crossref_primary_10_1126_science_abn7591 crossref_primary_10_1002_mco2_115 crossref_primary_10_3390_ijms24054398 crossref_primary_10_1038_s41467_023_39189_8 crossref_primary_10_2478_jtim_2022_0026 crossref_primary_10_1016_j_virs_2022_10_006 crossref_primary_10_3389_fmed_2021_806641 crossref_primary_10_1016_j_apsb_2023_05_030 crossref_primary_10_1128_jvi_01223_24 crossref_primary_10_1128_Spectrum_00341_21 crossref_primary_10_1093_pcmedi_pbab016 crossref_primary_10_1016_S0140_6736_21_02183_8 crossref_primary_10_1080_14760584_2021_1976153 crossref_primary_10_1002_eji_202149535 crossref_primary_10_1186_s43141_022_00431_3 crossref_primary_10_1038_s41421_021_00320_y crossref_primary_10_1002_mco2_95 crossref_primary_10_1039_D2SC06665C crossref_primary_10_3390_vaccines9101082 crossref_primary_10_1002_mco2_90 crossref_primary_10_3390_pharmaceutics14020398 crossref_primary_10_1093_pcmedi_pbab024 crossref_primary_10_1186_s12951_024_02345_3 crossref_primary_10_1016_j_celrep_2025_115499 crossref_primary_10_1038_s41590_022_01163_9 crossref_primary_10_1002_advs_202104333 crossref_primary_10_1080_01932691_2024_2434704 crossref_primary_10_1007_s11356_022_24901_w crossref_primary_10_1093_intimm_dxac064 crossref_primary_10_3390_ijms23179566 crossref_primary_10_1080_22221751_2021_1994356 crossref_primary_10_1038_s41467_022_29477_0 crossref_primary_10_1038_s41576_021_00408_x crossref_primary_10_1007_s12015_022_10477_y crossref_primary_10_1073_pnas_2120976119 crossref_primary_10_1089_vbz_2021_0080 crossref_primary_10_4103_1995_7645_359789 crossref_primary_10_1080_22221751_2021_2008775 crossref_primary_10_3389_fmicb_2022_851323 crossref_primary_10_1016_j_jcvp_2022_100130 crossref_primary_10_1038_s41541_024_00961_6 crossref_primary_10_1093_intimm_dxac031 crossref_primary_10_1002_cbin_12130 crossref_primary_10_1186_s12985_022_01944_6 crossref_primary_10_1002_jmv_27951 crossref_primary_10_3390_v13102011 crossref_primary_10_2147_IDR_S341694 crossref_primary_10_1016_j_inoche_2024_113843 crossref_primary_10_1007_s12033_024_01146_1 crossref_primary_10_1038_s41392_022_00996_y crossref_primary_10_1016_j_lanwpc_2022_100586 crossref_primary_10_1016_j_cmi_2022_01_011 crossref_primary_10_3390_microorganisms9091794 crossref_primary_10_1042_BST20210859 crossref_primary_10_3389_fcimb_2021_777212 crossref_primary_10_3389_fimmu_2024_1259788 crossref_primary_10_1002_cyto_a_24484 crossref_primary_10_1002_jmv_27717 crossref_primary_10_1016_j_jinf_2022_02_033 crossref_primary_10_3390_ijms22147425 crossref_primary_10_1038_s41598_022_09845_y crossref_primary_10_2147_NSS_S380141 crossref_primary_10_1038_s41586_021_04389_z crossref_primary_10_3390_vaccines10081170 crossref_primary_10_1016_j_isci_2024_110174 crossref_primary_10_1371_journal_pone_0287377 crossref_primary_10_1016_j_cmi_2021_10_005 crossref_primary_10_1126_sciimmunol_abq2427 crossref_primary_10_1126_scitranslmed_abn4338 crossref_primary_10_1016_j_jvacx_2025_100664 crossref_primary_10_1186_s12879_022_07374_7 crossref_primary_10_3390_jpm11090886 crossref_primary_10_3389_fmed_2021_836826 crossref_primary_10_3390_ijms221910559 crossref_primary_10_1093_infdis_jiab635 crossref_primary_10_3390_cells11010067 crossref_primary_10_1093_jtm_taab118 crossref_primary_10_1016_j_cca_2021_10_028 crossref_primary_10_3390_jfb16050185 crossref_primary_10_1007_s40200_022_01002_6 crossref_primary_10_1038_s41467_022_28317_5 crossref_primary_10_1126_scitranslmed_abq1945 crossref_primary_10_1186_s13073_021_00985_w crossref_primary_10_3389_fmolb_2023_1205919 crossref_primary_10_1002_jmv_28032 crossref_primary_10_1007_s10875_022_01354_x crossref_primary_10_1186_s12985_023_02025_y crossref_primary_10_1128_Spectrum_01128_21 crossref_primary_10_1002_advs_202202556 crossref_primary_10_1016_j_compbiomed_2023_106618 crossref_primary_10_1136_annrheumdis_2021_221097 crossref_primary_10_3389_fmed_2022_903876 crossref_primary_10_1038_s41467_022_31930_z crossref_primary_10_3389_fmed_2022_828819 crossref_primary_10_1007_s13555_021_00610_z crossref_primary_10_3390_jdb9040058 crossref_primary_10_3390_vaccines10040521 crossref_primary_10_1016_j_virol_2025_110675 crossref_primary_10_1126_sciimmunol_abl5344 crossref_primary_10_3390_molecules27248957 crossref_primary_10_1038_s41467_023_37972_1 crossref_primary_10_1002_med_21941 crossref_primary_10_2215_CJN_11820921 crossref_primary_10_1016_j_ejmech_2025_117709 crossref_primary_10_3389_fimmu_2022_797589 crossref_primary_10_3390_ijms232113220 crossref_primary_10_3390_vaccines9101195 crossref_primary_10_1016_j_jmb_2021_167438 crossref_primary_10_1038_s41423_021_00772_y crossref_primary_10_3389_fimmu_2021_747830 crossref_primary_10_52711_2231_5659_2022_00025 crossref_primary_10_1007_s11684_021_0893_y crossref_primary_10_1126_scitranslmed_abj1996 crossref_primary_10_3389_fimmu_2022_786586 crossref_primary_10_17816_EID629244 |
| Cites_doi | 10.1056/NEJMoa2034577 10.1038/s41586-020-2012-7 10.1016/j.cell.2020.09.032 10.1038/s41586-020-2895-3 10.1038/s41586-021-03361-1 10.1038/s41467-020-20789-7 10.1038/s41596-021-00491-8 10.1038/s41541-021-00313-8 10.1371/journal.ppat.1003565 10.1016/j.cell.2020.06.043 10.1038/s41586-021-03275-y 10.1016/j.chom.2020.04.004 10.1038/s41467-020-17892-0 10.1056/NEJMoa2027906 10.1038/s41591-021-01270-4 10.1056/NEJMc2102017 10.1038/s41591-021-01294-w 10.1101/2021.03.18.435972 10.1101/2021.05.04.442663 10.1056/NEJMc2106083 10.1101/2021.03.08.434499 10.1101/2021.05.14.444076 10.1101/2021.05.22.21257658 10.1101/2021.02.22.432189 10.1101/2021.05.09.443299 10.1126/science.abe8499 10.1056/NEJMc2104974 10.1038/s41586-021-03653-6 |
| ContentType | Journal Article |
| Copyright | The Author(s), under exclusive licence to Springer Nature Limited 2021 2021. The Author(s), under exclusive licence to Springer Nature Limited. COPYRIGHT 2021 Nature Publishing Group Copyright Nature Publishing Group Aug 12, 2021 |
| Copyright_xml | – notice: The Author(s), under exclusive licence to Springer Nature Limited 2021 – notice: 2021. The Author(s), under exclusive licence to Springer Nature Limited. – notice: COPYRIGHT 2021 Nature Publishing Group – notice: Copyright Nature Publishing Group Aug 12, 2021 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM ATWCN 3V. 7QG 7QL 7QP 7QR 7RV 7SN 7SS 7ST 7T5 7TG 7TK 7TM 7TO 7U9 7X2 7X7 7XB 88A 88E 88G 88I 8AF 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK 8G5 ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BEC BENPR BGLVJ BHPHI BKSAR C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M2M M2O M2P M7N M7P M7S MBDVC NAPCQ P5Z P62 P64 PATMY PCBAR PDBOC PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ PTHSS PYCSY Q9U R05 RC3 S0X SOI 7X8 |
| DOI | 10.1038/s41586-021-03693-y |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Middle School ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Environment Abstracts Immunology Abstracts Meteorological & Geoastrophysical Abstracts Neurosciences Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) Materials Science & Engineering Collection ProQuest Central (Alumni) One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Computer Science Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection eLibrary AUTh Library subscriptions: ProQuest Central Technology Collection Natural Science Collection Earth, Atmospheric & Aquatic Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agriculture Science Database ProQuest Health & Medical Collection Medical Database Psychology Database Research Library Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Research Library (Corporate) Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Earth, Atmospheric & Aquatic Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China One Psychology Engineering Collection Environmental Science Collection ProQuest Central Basic University of Michigan Genetics Abstracts SIRS Editorial Environment Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database ProQuest One Psychology Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection Chemoreception Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Earth, Atmospheric & Aquatic Science Database Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) University of Michigan Technology Collection Technology Research Database ProQuest One Academic Middle East (New) SIRS Editorial Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Biology Journals (Alumni Edition) ProQuest Central Earth, Atmospheric & Aquatic Science Collection ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Research Library ProQuest Materials Science Collection ProQuest Public Health ProQuest Central Basic ProQuest Science Journals ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library ProQuest Psychology Journals Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts Environment Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Agricultural Science Database |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: PATMY name: Environmental Science Database url: http://search.proquest.com/environmentalscience sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) Physics |
| EISSN | 1476-4687 |
| EndPage | 275 |
| ExternalDocumentID | A671657901 34111888 10_1038_s41586_021_03693_y |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United States United Kingdom--UK Nigeria United States--US India |
| GeographicLocations_xml | – name: United States – name: Nigeria – name: United Kingdom--UK – name: United States--US – name: India |
| GroupedDBID | --- --Z -DZ -ET -~X .55 .CO .XZ 07C 0R~ 0WA 123 186 1OL 1VR 29M 2KS 2XV 39C 41X 53G 5RE 6TJ 70F 7RV 7X2 7X7 7XC 85S 88A 88E 88I 8AF 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ 8G5 8R4 8R5 8WZ 97F 97L A6W A7Z AAEEF AAHBH AAHTB AAIKC AAKAB AAMNW AASDW AAVBQ AAYEP AAYZH AAZLF ABDQB ABFSI ABIVO ABJCF ABJNI ABLJU ABOCM ABPEJ ABPPZ ABUWG ABWJO ABZEH ACBEA ACBWK ACGFO ACGFS ACGOD ACIWK ACKOT ACMJI ACNCT ACPRK ACWUS ADBBV ADFRT ADUKH AENEX AEUYN AFBBN AFFNX AFKRA AFLOW AFRAH AFSHS AGAYW AGHSJ AGHTU AGOIJ AGSOS AHMBA AHSBF AIDUJ ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMTXH ARAPS ARMCB ASPBG ATCPS ATWCN AVWKF AXYYD AZFZN AZQEC BBNVY BCU BEC BENPR BGLVJ BHPHI BIN BKEYQ BKKNO BKSAR BPHCQ BVXVI CCPQU CJ0 CS3 D1I D1J D1K DU5 DWQXO E.- E.L EAP EBS EE. EMH EPS EX3 EXGXG F5P FEDTE FQGFK FSGXE FYUFA GNUQQ GUQSH HCIFZ HG6 HMCUK HVGLF HZ~ IAO ICQ IEA IEP IGS IH2 IHR INH INR IOF IPY ISR ITC K6- KB. KOO L6V L7B LK5 LK8 LSO M0K M1P M2M M2O M2P M7P M7R M7S N9A NAPCQ NEPJS O9- OBC OES OHH OMK OVD P2P P62 PATMY PCBAR PDBOC PKN PQQKQ PROAC PSQYO PSYQQ PTHSS PYCSY Q2X R05 RND RNS RNT RNTTT RXW S0X SC5 SHXYY SIXXV SJFOW SJN SNYQT SOJ TAE TAOOD TBHMF TDRGL TEORI TN5 TSG TWZ U5U UIG UKHRP UKR UMD UQL VQA VVN WH7 WOW X7M XIH XKW XZL Y6R YAE YCJ YFH YIF YIN YNT YOC YQT YR2 YR5 YXB YZZ Z5M ZCA ~02 ~7V ~88 ~KM AARCD AAYXX ABFSG ABUFD ACSTC AEZWR AFANA AFFHD AFHIU AGSTI AHWEU AIXLP ALPWD ATHPR CITATION PHGZM PHGZT PJZUB PPXIY PQGLB TUS .-4 .GJ .HR 00M 08P 1CY 1VW 354 3EH 3O- 4.4 41~ 42X 4R4 663 79B 9M8 A8Z AAJYS AAKAS ABAWZ ABDBF ABDPE ABEFU ABNNU ACBNA ACBTR ACRPL ACTDY ACUHS ADGHP ADNMO ADRHT ADXHL ADYSU ADZCM AETEA AFFDN AFHKK AGCDD AGGDT AGNAY AGQPQ AIDAL AIYXT AJUXI APEBS ARTTT B0M BCR BDKGC BES BKOMP BLC CGR CUY CVF DB5 DO4 EAD EAS EAZ EBC EBD EBO ECC ECM EIF EJD EMB EMF EMK EMOBN EPL ESE ESN ESX FA8 FAC I-F J5H L-9 LGEZI LOTEE MVM N4W NADUK NEJ NFIDA NPM NXXTH ODYON OHT P-O PEA PM3 PV9 QS- R4F RHI SKT SV3 TH9 TUD UBY UHB USG VOH X7L XOL YJ6 YQI YQJ YV5 YXA YYP YYQ ZCG ZE2 ZGI ZHY ZKB ZY4 ~8M ~G0 ACMFV AEIIB PMFND 3V. 7QG 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7TG 7TK 7TM 7TO 7U9 7XB 8FD 8FK C1K FR3 H94 K9. KL. M7N MBDVC P64 PKEHL PQEST PQUKI PRINS Q9U RC3 SOI 7X8 PUEGO |
| ID | FETCH-LOGICAL-c687t-ac5e75873bc8154399b7ba5ca295a9a6f65a624f6d2d877e36575ae7fbf9178c3 |
| IEDL.DBID | M2M |
| ISICitedReferencesCount | 221 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000671733700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0028-0836 1476-4687 |
| IngestDate | Wed Oct 01 10:54:57 EDT 2025 Tue Oct 07 06:53:01 EDT 2025 Tue Nov 11 10:21:19 EST 2025 Sat Nov 29 11:34:36 EST 2025 Tue Jun 10 15:35:00 EDT 2025 Tue Nov 04 18:06:06 EST 2025 Thu Nov 13 14:23:46 EST 2025 Thu Nov 13 15:29:36 EST 2025 Mon Jul 21 06:02:23 EDT 2025 Sat Nov 29 03:48:49 EST 2025 Tue Nov 18 21:54:34 EST 2025 Fri Feb 21 02:37:08 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7871 |
| Language | English |
| License | 2021. The Author(s), under exclusive licence to Springer Nature Limited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c687t-ac5e75873bc8154399b7ba5ca295a9a6f65a624f6d2d877e36575ae7fbf9178c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-8016-8556 0000-0003-4561-2273 0000-0001-5553-1616 0000-0003-0671-6360 0000-0002-3389-8414 0000-0002-2520-7038 0000-0003-0918-016X |
| OpenAccessLink | https://www.nature.com/articles/s41586-021-03693-y.pdf |
| PMID | 34111888 |
| PQID | 2561110250 |
| PQPubID | 40569 |
| PageCount | 3 |
| ParticipantIDs | proquest_miscellaneous_2540518335 proquest_journals_2561110250 gale_infotracmisc_A671657901 gale_infotracgeneralonefile_A671657901 gale_infotraccpiq_671657901 gale_infotracacademiconefile_A671657901 gale_incontextgauss_ISR_A671657901 gale_incontextgauss_ATWCN_A671657901 pubmed_primary_34111888 crossref_citationtrail_10_1038_s41586_021_03693_y crossref_primary_10_1038_s41586_021_03693_y springer_journals_10_1038_s41586_021_03693_y |
| PublicationCentury | 2000 |
| PublicationDate | 2021-08-12 |
| PublicationDateYYYYMMDD | 2021-08-12 |
| PublicationDate_xml | – month: 08 year: 2021 text: 2021-08-12 day: 12 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationSubtitle | International weekly journal of science |
| PublicationTitle | Nature (London) |
| PublicationTitleAbbrev | Nature |
| PublicationTitleAlternate | Nature |
| PublicationYear | 2021 |
| Publisher | Nature Publishing Group UK Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
| References | Liu (CR4) 2021; 384 Zou (CR17) 2021; 6 Korber (CR8) 2020; 182 Zhou (CR11) 2021; 592 CR18 Walsh (CR21) 2020; 383 CR13 Zhou (CR7) 2020; 579 Xie (CR19) 2020; 27 Xie (CR29) 2021; 16 Wan, Shang, Graham, Baric, Li (CR12) 2020; 94 Plante (CR3) 2021; 592 Xie (CR2) 2021; 27 CR5 CR28 CR27 CR26 Ku (CR14) 2021; 12 CR25 CR24 CR23 CR22 CR20 Hou (CR10) 2020; 370 Vogel (CR16) 2021; 592 Muruato (CR30) 2020; 11 Chen (CR1) 2021; 27 Yurkovetskiy (CR9) 2020; 183 Smith, Blanc, Surdel, Vignuzzi, Denison (CR6) 2013; 9 Polack (CR15) 2020; 383 L Yurkovetskiy (3693_CR9) 2020; 183 EC Smith (3693_CR6) 2013; 9 B Zhou (3693_CR11) 2021; 592 Y Liu (3693_CR4) 2021; 384 X Xie (3693_CR19) 2020; 27 X Xie (3693_CR29) 2021; 16 X Xie (3693_CR2) 2021; 27 3693_CR5 AB Vogel (3693_CR16) 2021; 592 3693_CR13 AE Muruato (3693_CR30) 2020; 11 3693_CR18 P Zhou (3693_CR7) 2020; 579 JA Plante (3693_CR3) 2021; 592 Y Wan (3693_CR12) 2020; 94 Z Ku (3693_CR14) 2021; 12 3693_CR20 RE Chen (3693_CR1) 2021; 27 B Korber (3693_CR8) 2020; 182 YJ Hou (3693_CR10) 2020; 370 EE Walsh (3693_CR21) 2020; 383 3693_CR27 3693_CR28 FP Polack (3693_CR15) 2020; 383 3693_CR25 J Zou (3693_CR17) 2021; 6 3693_CR26 3693_CR23 3693_CR24 3693_CR22 |
| References_xml | – ident: CR22 – volume: 383 start-page: 2603 year: 2020 end-page: 2615 ident: CR15 article-title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2034577 – ident: CR18 – volume: 579 start-page: 270 year: 2020 end-page: 273 ident: CR7 article-title: A pneumonia outbreak associated with a new coronavirus of probable bat origin publication-title: Nature doi: 10.1038/s41586-020-2012-7 – volume: 183 start-page: 739 year: 2020 end-page: 751.e8 ident: CR9 article-title: Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant publication-title: Cell doi: 10.1016/j.cell.2020.09.032 – volume: 592 start-page: 116 year: 2021 end-page: 121 ident: CR3 article-title: Spike mutation D614G alters SARS-CoV-2 fitness publication-title: Nature doi: 10.1038/s41586-020-2895-3 – ident: CR25 – volume: 592 start-page: 122 year: 2021 end-page: 127 ident: CR11 article-title: SARS-CoV-2 spike D614G change enhances replication and transmission publication-title: Nature doi: 10.1038/s41586-021-03361-1 – ident: CR27 – volume: 12 year: 2021 ident: CR14 article-title: Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape publication-title: Nat. Commun. doi: 10.1038/s41467-020-20789-7 – ident: CR23 – volume: 94 year: 2020 ident: CR12 article-title: Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus publication-title: J. Virol. – volume: 16 start-page: 1761 year: 2021 end-page: 1784 ident: CR29 article-title: Engineering SARS-CoV-2 using a reverse genetic system publication-title: Nat. Protocols doi: 10.1038/s41596-021-00491-8 – volume: 6 year: 2021 ident: CR17 article-title: The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization publication-title: NPJ Vaccines doi: 10.1038/s41541-021-00313-8 – volume: 9 year: 2013 ident: CR6 article-title: Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1003565 – volume: 182 start-page: 812 year: 2020 end-page: 827.e19 ident: CR8 article-title: Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus publication-title: Cell doi: 10.1016/j.cell.2020.06.043 – volume: 592 start-page: 283 year: 2021 end-page: 289 ident: CR16 article-title: BNT162b vaccines protect rhesus macaques from SARS-CoV-2 publication-title: Nature doi: 10.1038/s41586-021-03275-y – volume: 27 start-page: 841 year: 2020 end-page: 848.e3 ident: CR19 article-title: An infectious cDNA clone of SARS-CoV-2 publication-title: Cell Host Microbe doi: 10.1016/j.chom.2020.04.004 – volume: 11 year: 2020 ident: CR30 article-title: A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation publication-title: Nat. Commun. doi: 10.1038/s41467-020-17892-0 – ident: CR13 – volume: 383 start-page: 2439 year: 2020 end-page: 2450 ident: CR21 article-title: Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2027906 – ident: CR5 – volume: 27 start-page: 620 year: 2021 end-page: 621 ident: CR2 article-title: Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera publication-title: Nat. Med. doi: 10.1038/s41591-021-01270-4 – volume: 384 start-page: 1466 year: 2021 end-page: 1468 ident: CR4 article-title: Neutralizing activity of BNT162b2-elicited serum publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2102017 – ident: CR28 – ident: CR26 – volume: 27 start-page: 717 year: 2021 end-page: 726 ident: CR1 article-title: Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies publication-title: Nat. Med. doi: 10.1038/s41591-021-01294-w – ident: CR24 – volume: 370 start-page: 1464 year: 2020 end-page: 1468 ident: CR10 article-title: SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo publication-title: Science – ident: CR20 – volume: 6 year: 2021 ident: 3693_CR17 publication-title: NPJ Vaccines doi: 10.1038/s41541-021-00313-8 – ident: 3693_CR27 doi: 10.1101/2021.03.18.435972 – volume: 384 start-page: 1466 year: 2021 ident: 3693_CR4 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2102017 – volume: 183 start-page: 739 year: 2020 ident: 3693_CR9 publication-title: Cell doi: 10.1016/j.cell.2020.09.032 – volume: 94 year: 2020 ident: 3693_CR12 publication-title: J. Virol. – volume: 592 start-page: 122 year: 2021 ident: 3693_CR11 publication-title: Nature doi: 10.1038/s41586-021-03361-1 – ident: 3693_CR23 doi: 10.1101/2021.05.04.442663 – ident: 3693_CR5 doi: 10.1056/NEJMc2106083 – ident: 3693_CR13 doi: 10.1101/2021.03.08.434499 – volume: 383 start-page: 2603 year: 2020 ident: 3693_CR15 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2034577 – volume: 16 start-page: 1761 year: 2021 ident: 3693_CR29 publication-title: Nat. Protocols doi: 10.1038/s41596-021-00491-8 – volume: 27 start-page: 620 year: 2021 ident: 3693_CR2 publication-title: Nat. Med. doi: 10.1038/s41591-021-01270-4 – ident: 3693_CR20 doi: 10.1101/2021.05.14.444076 – ident: 3693_CR26 doi: 10.1101/2021.05.22.21257658 – volume: 9 year: 2013 ident: 3693_CR6 publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1003565 – ident: 3693_CR24 doi: 10.1101/2021.02.22.432189 – volume: 182 start-page: 812 year: 2020 ident: 3693_CR8 publication-title: Cell doi: 10.1016/j.cell.2020.06.043 – volume: 592 start-page: 116 year: 2021 ident: 3693_CR3 publication-title: Nature doi: 10.1038/s41586-020-2895-3 – volume: 27 start-page: 717 year: 2021 ident: 3693_CR1 publication-title: Nat. Med. doi: 10.1038/s41591-021-01294-w – volume: 27 start-page: 841 year: 2020 ident: 3693_CR19 publication-title: Cell Host Microbe doi: 10.1016/j.chom.2020.04.004 – volume: 383 start-page: 2439 year: 2020 ident: 3693_CR21 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2027906 – ident: 3693_CR22 doi: 10.1101/2021.05.09.443299 – volume: 370 start-page: 1464 year: 2020 ident: 3693_CR10 publication-title: Science doi: 10.1126/science.abe8499 – ident: 3693_CR25 doi: 10.1056/NEJMc2104974 – volume: 579 start-page: 270 year: 2020 ident: 3693_CR7 publication-title: Nature doi: 10.1038/s41586-020-2012-7 – ident: 3693_CR18 – volume: 12 year: 2021 ident: 3693_CR14 publication-title: Nat. Commun. doi: 10.1038/s41467-020-20789-7 – volume: 592 start-page: 283 year: 2021 ident: 3693_CR16 publication-title: Nature doi: 10.1038/s41586-021-03275-y – ident: 3693_CR28 doi: 10.1038/s41586-021-03653-6 – volume: 11 year: 2020 ident: 3693_CR30 publication-title: Nat. Commun. doi: 10.1038/s41467-020-17892-0 |
| SSID | ssj0005174 |
| Score | 2.703914 |
| Snippet | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve around the world, generating new variants that are of concern on the basis... |
| SourceID | proquest gale pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 273 |
| SubjectTerms | 13 38/23 38/77 38/90 631/326/590/2293 631/326/596/4130 Animals Antibodies Antibodies, Neutralizing - blood Antibodies, Neutralizing - immunology Antibodies, Viral - blood Antibodies, Viral - immunology Binding sites BNT162 Vaccine Causes of Chemical compounds Chlorocebus aethiops Coronaviruses COVID-19 COVID-19 - immunology COVID-19 - prevention & control COVID-19 - virology COVID-19 vaccines COVID-19 Vaccines - genetics COVID-19 Vaccines - immunology Disease transmission Glycoproteins Health aspects Humanities and Social Sciences Humans Immunization Medical research Medicine, Experimental mRNA Vaccines multidisciplinary Mutation Neutralization Neutralization Tests Pandemics Pathogenicity Pathogens Pharmacology SARS-CoV-2 - genetics SARS-CoV-2 - immunology Science Science (multidisciplinary) Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Spike Glycoprotein, Coronavirus - chemistry Spike Glycoprotein, Coronavirus - genetics Spike Glycoprotein, Coronavirus - immunology Vaccines Vaccines, Synthetic - genetics Vero Cells Viral diseases Viruses |
| Title | BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants |
| URI | https://link.springer.com/article/10.1038/s41586-021-03693-y https://www.ncbi.nlm.nih.gov/pubmed/34111888 https://www.proquest.com/docview/2561110250 https://www.proquest.com/docview/2540518335 |
| Volume | 596 |
| WOSCitedRecordID | wos000671733700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAQT databaseName: Nature customDbUrl: eissn: 1476-4687 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0005174 issn: 0028-0836 databaseCode: RNT dateStart: 19970101 isFulltext: true titleUrlDefault: https://www.nature.com providerName: Nature Publishing – providerCode: PRVPQU databaseName: Advanced Technologies & Aerospace Database customDbUrl: eissn: 1476-4687 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0005174 issn: 0028-0836 databaseCode: P5Z dateStart: 19880107 isFulltext: true titleUrlDefault: https://search.proquest.com/hightechjournals providerName: ProQuest – providerCode: PRVPQU databaseName: Agriculture Science Database customDbUrl: eissn: 1476-4687 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0005174 issn: 0028-0836 databaseCode: M0K dateStart: 19880107 isFulltext: true titleUrlDefault: https://search.proquest.com/agriculturejournals providerName: ProQuest – providerCode: PRVPQU databaseName: Biological Science Database (Proquest) customDbUrl: eissn: 1476-4687 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0005174 issn: 0028-0836 databaseCode: M7P dateStart: 19880107 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Earth, Atmospheric & Aquatic Science Database customDbUrl: eissn: 1476-4687 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0005174 issn: 0028-0836 databaseCode: PCBAR dateStart: 19880107 isFulltext: true titleUrlDefault: https://search.proquest.com/eaasdb providerName: ProQuest – providerCode: PRVPQU databaseName: Engineering Database customDbUrl: eissn: 1476-4687 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0005174 issn: 0028-0836 databaseCode: M7S dateStart: 19880107 isFulltext: true titleUrlDefault: http://search.proquest.com providerName: ProQuest – providerCode: PRVPQU databaseName: Environmental Science Database customDbUrl: eissn: 1476-4687 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0005174 issn: 0028-0836 databaseCode: PATMY dateStart: 19880107 isFulltext: true titleUrlDefault: http://search.proquest.com/environmentalscience providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1476-4687 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0005174 issn: 0028-0836 databaseCode: 7X7 dateStart: 19880107 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Materials Science Database customDbUrl: eissn: 1476-4687 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0005174 issn: 0028-0836 databaseCode: KB. dateStart: 19880107 isFulltext: true titleUrlDefault: http://search.proquest.com/materialsscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1476-4687 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0005174 issn: 0028-0836 databaseCode: 7RV dateStart: 19880107 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1476-4687 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0005174 issn: 0028-0836 databaseCode: BENPR dateStart: 19880107 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1476-4687 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0005174 issn: 0028-0836 databaseCode: M2M dateStart: 19880107 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1476-4687 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0005174 issn: 0028-0836 databaseCode: 8C1 dateStart: 19880107 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1476-4687 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0005174 issn: 0028-0836 databaseCode: M2O dateStart: 19880107 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1476-4687 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0005174 issn: 0028-0836 databaseCode: M2P dateStart: 19880107 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1db9Mw0GIbSLwAGzDCRhXQxIeYu8T5sPOE2moT02ip2jIqXqzYSaZKU9It7aT9e86O2y7V2AsvJ0W-WHHu2747I3Tg-JkA0gbYiROCVQcuHIWS4oQwkSWRL4TQhcI_aK_HxuOobzbcSpNWudCJWlEnhVR75EdgmkEslcX-Nr3C6tYodbpqrtDYQFvgKDMlmF3SXaV4rHVhNkUzjseOSjBcTKXfqoSiMPLwbc0wravnO_Zp7cBU26GT5_-7ghfomfFA7VbFMtvoUZrvoCc6E1SWO2jbSHtpfzYtqb-8RKft3sgNiSA4vZxI5aXaeTrXmyRVGaddZHa76TbBU7HjPLF1XZc9bA2GuFOcY2LfQEyuUm5eoV8nx6POd2wuYcAyZHSGYxmkEFNQT0gG7hb4M4KKOJAxiYI4isMsDOKQ-FmYkIRRmnrqJCdOaSYyiASZ9F6jzbzI0zfIziIIhxISJb7n-JIIkTjCk5IxmNHPiLCQu6AAl6ZDuboo45Lrk3KP8YpqHKjGNdX4rYW-Lt-ZVv05HsQ-UITlqvFFrjJrLuJ5WfLW6Henx1shxI4BBQfJQh_uQzsdDmpInwxSVsBXytjUM8BaVUutGuZeDVNOJ1f8zujH2uhFRdv7ptmvIYIekPXhBdtxo4dKvuI5C71fDqs3VW5dnhZzhQNOu6uK7yy0W3H58leCj6MEi1nocMH2q8n__Z_fPvwte-gp0ZLHsEv20ebsep6-Q4_lzWxSXjfQBh2cKzimGjKArOM20Fb7uNcfwNNZuwmw65w1tLxr-FPDvoK0gkOA_eDPX0mFUGY |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1JbxMxFH4qBQQXoGUbWsCgsgncJp7Nc0AoDVSNGlLUBOjN2J6ZKlI1k3aSovwpfiPPsySdqPTWA2c_W17ean_vGWCj4cQKj9alDRkyaipw0cDTPg0ZV3EYOEqpPFG46_d6_PAw-LYEf6pcGAOrrHRirqjDVJs78i00zSiWxmJ_Gp1Q82uUeV2tvtAo2GIvmv7GkC372PmM5_uKsZ0vg_YuLX8VoNrj_phK7UboJPu20hz9BzTQylfS1ZIFrgykF3uu9JgTeyELue9HtnmakJEfqxhDG65tHPcaXHdMJGSggmx_DilZqPpcJuk0bL6VoaHkBu5rAExeYNNpzRAumoNz9nDhgTa3ezt3_7cduwd3Sg-btAqRWIGlKFmFmznSVWersFJqs4y8LUtuv7sPne3eoOkxxWh0PNTGCydJNMkvgYo0VZLGZHuzuYmeGJFJSPK8NdJvHfRpO_1BGTmTKMnJOHsA369kcQ9hOUmT6DGQOMBwL2RB6NgNRzOlwoayteYcR3RipixoVicudFmB3XwEcixyJIDNRcElArlE5Fwipha8n_UZFfVHLqXeMIwkTGGPxCCHjuQky0Rr8LPdEy0PY2PXRwfQgpcXkXX6BzWiNyVRnOIstSzzNXCtpmRYjXKtRqlHwxNxrvV1rfWoONuLhlmvEaKe0_Xmis1FqWczMedxC17Mmk1Pgx1MonRiaDAoaZrkQgseFVI120r04TDC5tyCD5WYzQf_9z4_uXwuz-HW7uBrV3Q7vb01uM1yqee0ydZheXw6iZ7CDX02Hmanz3L9QeDXVYvfX8cgoc8 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD4a4yJegI1b2ICAxgCB19S5OQ8IdR0V1aaqWgtMvBjbSaZKU9It7VD_Gr-O41zapRp72wPPPrYSn7v9nWOALcuJJbLWJZYIKdEduEjgKZ-ElMk4DBwpZV4ofOD3euzoKOivwJ-qFkbDKiubmBvqMFX6jLyBrhnVUnvsRlzCIvp7nc_jU6JfkNI3rdVzGoWI7Eez35i-ZZ-6e8jrN5R2vgzbX0n5wgBRHvMnRCg3woDZt6ViGEugs5a-FK4SNHBFILzYc4VHndgLach8P7L1NYWI_FjGmOYwZeO6N-CmjzmmhhP23Z8LeMlSB-iyYMeyWSNDp8k09FeDmbzAJrOaU1x2DRd849Jlbe4DO_f_5917APfKyNtsFaqyBitRsg63cwSsytZhrbRymfmubMX9_iF0d3vDpkclJdHJSOno3EyiaX44VJSvmmls7u40dzBCM0USmnk9mzloHQ5IO_1OqHkuUMOTSfYIvl3Lzz2G1SRNoqdgxgGmgSENQse2HEWlDC1pK8UYrujEVBrQrLjPVdmZXT8QcsJzhIDNeCExHCWG5xLDZwZ8mM8ZF31JrqTe0kLFdcOPRDP_WEyzjLeGP9o93vIwZ3Z9DAwNeH0ZWXdwWCN6WxLFKX6lEmUdB_6rbiVWo9yoUarx6JRfGN2ujR4XvL1smc0aIdo_VR-uRJ6X9jfjC3k34NV8WM_UmMIkSqeaBpOVpi46NOBJoWHzrcTYDjNvxgz4WKncYvF_7_Ozq7_lJdxBreMH3d7-BtyluQFgpEk3YXVyNo2ewy11PhllZy9yU2LCr-vWvr-K3aq- |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=BNT162b2-elicited+neutralization+of+B.1.617+and+other+SARS-CoV-2+variants&rft.jtitle=Nature+%28London%29&rft.au=Liu%2C+Jianying&rft.au=Liu%2C+Yang&rft.au=Xia%2C+Hongjie&rft.au=Zou%2C+Jing&rft.date=2021-08-12&rft.pub=Nature+Publishing+Group+UK&rft.issn=0028-0836&rft.eissn=1476-4687&rft.volume=596&rft.issue=7871&rft.spage=273&rft.epage=275&rft_id=info:doi/10.1038%2Fs41586-021-03693-y&rft.externalDocID=10_1038_s41586_021_03693_y |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-0836&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-0836&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-0836&client=summon |